Latest Articles and Analysis

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Analyzes CMS marketplace rule changes and Medicaid expansion risks as pandemic emergency declarations end.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

HHS releases integrated Viral Hepatitis National Strategic Plan calling for a syndemic approach with HIV and STI.

Narrowly divided Senate limits Biden's health policy agenda, making regulatory actions the primary reform path.